Drugs

Dana-Farber’s Breast Oncology Center is leading a trial for stage 1 HER2+ Breast Cancer of T-DM1 followed by SQ trastuzumab versus TH

Photo taken from Dana-Farber’s Breast Oncology Center/X

Apr 8, 2024, 14:26

Dana-Farber’s Breast Oncology Center is leading a trial for stage 1 HER2+ Breast Cancer of T-DM1 followed by SQ trastuzumab versus TH

Dana-Farber’s Breast Oncology Center posted on X:

“We are leading a randomized Phase 2 trial for stage 1 HER2+ Breast Cancer of T-DM1 followed by SQ trastuzumab versus TH (paclitaxel + SQ trastuzumab) (ATEMPT 2.0).”

Read further.
Source: Dana-Farber’s Breast Oncology Center/X

Breast Cancer cancer clinical trial Dana-Farber Cancer Center Dana-Farber’s Breast Oncology Center HER2+ breast cancer OncoDaily Oncology Paclitaxel trastuzumab

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity